Expression of myocyte enhancer factor 2B in mantle cell lymphoma and its clinical significance / 中华病理学杂志

Objective@#To investigate the expression of myocyte enhancer factor 2B (MEF2B) in mantle cell lymphomas (MCL), and to analyze the correlation between the expression of MEF2B and pathological subtypes, structural subtypes, SOX11 expression and its clinical significance.@*Methods@#Paraffin-embedded tissues were stained with HE, immunohistochemistry (EnVision method) and fluorescence in situ hybridization (FISH) , in addition, the clinical and pathological data of 60 cases of MCL were collected at Sun Yat-sen University Foshan Hospital and Sun Yat-sen University Cancer Center from January,2002 to May, 2019 for analysis.@*Results@#Of the 60 MCLs, males is predominant (M∶F=3∶1). Histologically, the typical MCL is the majority (classical MCL: variant type MCL=48 cases:12 cases) . Fifty cases were classified into non-complete FDC meshwork type MCL, and the remaining 10 cases were classified into the complete-FDC meshwork type MCL group. Patients with classical MCL were more than 60 years old. The coexistent lesion sites both node and extranode in pathological subtype or structural subtype was the most common lesion sites. SOX11(+) MCL was common in classical MCL (P=0.040) and tended to be complete-FDC meshwork type MCL (P=0.086). The expression rate of MEF2B in MCL was 60.0%(36/60). This rate of MEF2B in classical type, complete-FDC meshwork type and SOX11(+) MCL was significantly higher than that variant type, no complete-FDC meshwork type, SOX11(-)MCL (P<0.05), respectively. There was no difference in clinical characteristics of MCL between MEF2B positive and negative groups. Compared with SOX11(-)MCL, the percentage of MEF2B expressed in tumor cells of SOX11(+)MCL was significantly higher (P=0.027). The expression of MEF2B was not related to the proliferation of tumor cells (P=0.341). There was no significant difference in the survival rate between different expression groups of MEF2B and SOX11 (P=0.304 and P=0.819, respectively). Only the mortality of variant type (blastoid/pleomorphic) MCL within 2 years was significantly higher than that of classical type MCL (P<0.05).@*Conclusions@#The expression of MEF2B in MCL is related to the pathological subtypes, structural subtypes and the expression of SOX11, but not to the proliferation and prognosis. The high mortality rate within 2 years is only found in variant MCL. However, the role of MEF2B in MCL needs to be further studied.

Relationship between uncoupling protein 2 gene promoter-866 G/A polymorphism and Chinese diabetic nephropathy / 中国医师进修杂志

Objective To investigate the relationship between uncoupling protein 2 (UCP-2) gene promoter -866 G/A polymorphism and Chinese diabetic nephropathy (DN). Methods A total of 182 patients with type 2 diabetic mellitus were selected and divided into DN group (90 cases with DN ) and NCD group (92 cases without DN ). Genomic DNA was detected, and UCP-2 genotype and allele gene frequency was confirmed by polymerase chain reaction-restrictive fragment length polymorphism, then compared.Results The genotype frequency of UCP-2 gene promoter-866 G/A polymorphism was distributed in DN group[GG 14.44%( 13/90),GA 31.11%(28/90),AA 54.44%(49/90)],and distributed in NCD group[GG 29.35% ( 27/92 ), GA 32.61% ( 30/92 ), AA 38.04% ( 35/92 )], and there was significant difference between two groups ( χ2 = 7.28 , P ＜ 0.05 ). There was also significant difference in allele gene frequency between DN group and NCD group[G 45.65% (84/184) vs. 30.00% (54/180),A 54.35% (100/184) vs. 70.00% (126/180)]( χ2 = 9.47, P ＜ 0.05 ). Conclusion There is correlation between the UCP-2 gene promoter-866 G/A polymorphism and Chinese DN, and the incidence of DN with A/A genotype is increased.

Observation of curative effect of repeated botulinium toxin type A treatment for Meige's syndrome in senile people / 中华老年医学杂志

Objective To investigate the efficacy and safety of repeated botulinum toxin type A (BTX-A) treatment for Meige's syndrome in senile people. Methods Forty-eight senile patients with Meige's syndrome received BTX-A treatment for twelve times or over. The improvements of spasm were evaluated before and after the first, the sixth and the twelfth treatment according to Cohen's criteria. The onset time, effective duration and side effects were studied and compared among the three times treatments. Results The obvious effective rate of the three times treatment were all 100%. The average onset time of the three times treatments were (3.5± 1.7)days,(3.2±1.8)days and (3.3±1.9)days, and the average effective duration were (25.4±2.1)weeks,(24.6±2.3)weeks and (25.4±1.8)weeks, respectively. The incidences of side effects were 8. 3% (4/48), 6.3(3/48)%and 8.3%(4/48), respectively. All the differences were not statistically significant(P>0.05). Conclusions Repeated BTX-A treatment is an effective and safe method for Meige's syndrome in senile people.

Botulinum toxin-A on treatment of hemifacial spasm and the changes of blink reflex by double stimulation before and after treatment / 中华神经科杂志

Objective To further observe the effect of botulinum toxin A(BTXA) treatment on hemifacial spasm(HFS) patients and to investigate the value of double stimulation of blink reflex(BR) before and after BTXA injection. Methods Among 134 cases of HFS treated by local injection of BTXA, the changes of BR in 42 cases was recorded before and after the injection. Results Of totally 134 treated cases, 60 (44 8%) cases were completely relieved and the rest 74 (55 2%) cases were obviously improved after treatment, with an effective duration of 16 5?5 7 weeks.In 42 patients with determination of BR value,before injection the latency of R 1, R 2, R' 2 of the affected side showed within normal limit.The interval of R 2 was shorter and the amplitudes of R 1,R 2,R' 2 were higher .After injection , the R 1 disappeared in 7 patients,and R 1,R 2,R' 2 all disappeared in 5 patients,for the rest 30 patients,the latency of R 1,R 2,R' 2 was prolonged slightly,but showing no apparent differences The amplitudes of R 1,R 2 and R' 2 were lowered significantly ( P

Botulinum Toxin Type A Therapy in Meige's Syndrome and Facial Wrinkles / 中华皮肤科杂志

Objective To observe the efficacy of Botulinum toxin type A(BTXA)injection in Meige's syndrome and facial wrinkles and exp lore the method of reducing the side e ffect of BTXAand weaken facial wrink les.Methods Ninety-nine patients were evaluate d on the therapeutic efficacy of single and multiple topical facial in-jection with BTXA.Results The effective rates of patients with blepharospasm were 98.4%,oromandi bular dystonia 90.9%,blepharospasm and o romandibular dystonia 95.8%,respectively.The therapeutic effect for each disease lasted(16.9?8.4)weeks?(12.6?5.4)weeks and(13.5?5.7)weeks,respectively.Facial wrinkl es of all patients has got weakened and seemed much smooth and flattend.The rec overy rate approached to 100%.The local side effects were transient an d mild,and disappeared spontaneously.Conclusions The treatment of Meige's syndrome and facial wrinkles with BTXA could produce a significant impro vement,and is safe.Strictly observ e the procedures of injection,and use adequate dose of BTXA,the side effects o f BTXA can be decreased.